Protective effect of oleoylethanolamide on focal cerebral ischemia in mice

Chinese Pharmacological Bulletin

Volumn 25, Issue 9, 2009, Pages

  Yang, Li Chao ^a   Yang, Wu Shuang ^b   Zhou, Yu ^a   Jin, Xin ^a  

^a XIAMEN UNIVERSITY   (China)

^b Xiamen Traditional Chinese Medicine Hospital   (China)

Author keywords

Cerebral ischemia; Effective doses; Mice; Middle cerebral artery occlusion; Oleoylethanolamide; Optimal therapeutic time point; Reperfusion injury

Indexed keywords

N OLEOYLETHANOLAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN EDEMA; BRAIN INFARCTION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; MOUSE; NEUROLOGIC DISEASE; NEUROPROTECTION; NONHUMAN; OCCLUSIVE CEREBROVASCULAR DISEASE; REPERFUSION; TRANSIENT ISCHEMIC ATTACK;

EID: 72149118432     PISSN: 10011978     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Giuffrida A, Rodriguez de Fonseca F, Piomelli D. Quantification of bioactive acylethanolamides in rat plasma by electrospray mass spectrometry[J]. Anal Biochem, 2000,280(1):87-93. (Pubitemid 30210816)
2. Panikashvili D, Simeonidou C, Ben-Shabat S, et al. An endogenous cannabinoid (2-AG) is neuroprotective after brain injury[J]. Nature, 2001,413(6855):527-531 (Pubitemid 32938751)
3. Schabitz W R, Giuffrida A, Berger C, et al. Release of fatty acid amides in a patient with hemispheric stroke: a microdialysis study[J]. Stroke, 2002,3(8):2112-2114
4. Longa E Z, Weinstein P R, Carlson S, et al. Reversible middle cerebral artery occlusion without craniectomy in rats[J]. Stroke, 1989,20(1):84-91. (Pubitemid 19040218)
5. Bederson J B, Pitts L H, Tsuji M, et al. Rat middle cerebral artery occlusion: evaluation of model and development of neurologic examination[J]. Stroke, 1986,7(3):472-476 (Pubitemid 16085691)
6. Guzmán M, Lo Verme J, Fu J, et al. Oleoylethanolamide stimulates lipolysis by activating the nuclear receptor peroxisome proliferator-activated receptor α (PPAR-α)[J]. J Biol Chem, 2004,279(27):27849-27854
7. Fu J, Gaetani S, Oveisi F, et al. Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-α[J]. Nature, 2003,425(6953):90-93 (Pubitemid 37101723)
8. Zhang H L, Gu Z L, Qin Z H. Peroxisome proliferator-activated receptors and neurodegenerative diseases[J]. Chin Pharmacol Bull, 2006,22(4):397-402.
9. Deplanque D, Gelé P, Pétrault O, et al. Peroxisome proliferator-activated receptor-alpha activation as a mechanism of preventive neuroprotection induced by chronic fenofibrate treatment[J]. J Neurosci, 2003,23(15):6264-6271 (Pubitemid 36875628)
10. Inoue H, Jiang X F, Katayama T, et al. Brain protection by resveratrol and fenofibrate against stroke requires peroxisome proliferator-activated receptor alpha in mice[J]. Neurosci Lett, 2003,352(3):203-206 (Pubitemid 38367603)
11. Dong W P, Zhang X, Gao D K, et al. Resveratrols effect on acute phases of focal cerebral ischemic injury in mice[J]. Chin Pharmacol Bull, 2008,24(8):1032-1035
12. Pialat J B, Cho T H, Beuf O, et al. MRI monitoring of focal cerebral ischemia in peroxisome proliferator-activated receptor (PPAR)-deficient mice[J]. NMR Biomed, 2007,20(3):335-342 (Pubitemid 46824533)
13. Rothrock J F, Hart R G. Antithrombotic therapy in cerebrovascular disease[J]. Ann Intern Med, 1991,115(11):885-895